A case report of a 35-year-old woman with chronic migraine who had a 2-year history of severe pain that did not improve with medical therapy showed that peripheral nerve field stimulation could safely treat chronic migraine.
Peripheral nerve field stimulation (PNFS), also known as subcutaneous stimulation, is a safe neuromodulation therapy for treating refractory chronic migraine (CM), according to a recent study.
The case report, published by Journal of Pain Research, evaluated a 35-year-old woman diagnosed with CM, who had a 2-year history of severe pain at the occipitocervical and left auriculotemporal area that did not improve with medical therapy. The researchers used exploratory PNFS at the preauricular area following failed attempts of occipital nerve simulation and PNFS at the retroauricular area.
“Unlike spinal cord stimulation (SCS) where leads are placed in the epidural space, leads of PNFS are placed into the subcutaneous tissue in the area of pain, thereby subcutaneously stimulating the peripheral nerves and their endings in the corresponding region to reach the spinal cord through the sensory afferent fibers and achieve analgesic effects,” explained the authors. “PNFS is mainly used for lower back pain, failed spinal surgery, head and face pain, and as an adjuvant therapy to SCS.”
During the procedure, the lead was led upward near the left ear, then to the temporal part of the brain through the ear—to the patient’s identified pain area. The patient was unsatisfied with the analgesic effect and therefore the lead was moved to the upper part of the mandibular joint.
Once the researchers found a satisfactory analgesic effect, pain in the temporal and occipital region was significantly relieved. The patient experienced an improvement in quality of life and decided to undergo an implantation, which continued to be effective in the 2-year follow-up without any adverse events.
“Perhaps one of the most important reasons for successful PNFS treatment for CM, in this case, is because of the patient’s sufficient trust and active compliance during the treatment period. Regards the underlying mechanism, it may be that the relatively thin muscle fibers in the temporal to anterior auricular area made it easier for the electrode to stimulate the nerve branches in the superficial fascia,” the authors wrote.
The researchers suggested that the case report results could be used in the future for developing a novel approach of PNFS application.
“The application of PNFS is very extensive. It is a choice for intractable CM characterized by temporal pain that can achieve ideal clinical effects and is still safe,” noted the authors. “However, the current circumstances call for advanced related mechanisms study, standardized operation guides, and large sample [randomized controlled trials] to promote the application of PNFS.”
Reference
Li Y, Mao P, Zhu Q, et al. Peripheral nerve field stimulation to the preauricular area for intractable chronic migraine: a case report [published online May 24, 2019]. Journal of Pain Research. doi: 10.2147/JPR.S196214.
Etonogestrel Contraceptive Implants Reduce Pain Crises in Women With Sickle Cell Disease
October 23rd 2024Etonogestrel-releasing contraceptive implants in women with sickle cell disease significantly reduced pain intensity and frequency of pain crises over 12 months, with no adverse changes in metabolic or liver function markers.
Read More
Building Trust, Breaking Barriers: Health Care Leaders Tackle Primary Care Challenges
August 8th 2024On this episode of Managed Care Cast, we're talking with the chief medical officers of CVS Health and Aetna, as well as CVS Health's chief health equity officer, about primary and preventive care engagement, the impact of telehealth, and the role of trust in patient-provider relationships.
Listen
Frameworks for Advancing Health Equity: Health Equity by Design
July 23rd 2024Melissa Clarke, MD, CMQ, the chief health equity officer at Elevance Health, explains "Health Equity by Design" and how Elevance Health is committed to ensuring a personalized and intentional approach for all its members.
Listen
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More